References
- Lowitt MH, Dover JS. Necrobiosis lipoidica. J Am Acad Dermatol. 1991;25(5):735–748. doi:10.1016/S0190-9622(08)80961-9
- Reid SD, Ladizinski B, Lee K, Baibergenova A, Alavi A. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol. 2013;69(5):783–791. doi:10.1016/j.jaad.2013.05.034
- Muller SA, Winkelmann RK. Necrobiosis lipoidica diabeticorum: a clinical and pathological investigation of 171 cases. Arch Dermatol. 1966;93(3):272–281. doi:10.1001/archderm.1966.01600210008002
- Ngo B, Wigington G, Hayes K, et al. Skin blood flow in necrobiosis lipoidica diabeticorum. Int J Dermatol. 2008;47(4):354–358. doi:10.1111/j.1365-4632.2008.03549.x
- Wang A, Singh K, Ibrahim W, King B, Damsky W. The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the literature. Yale J Biol Med. 2020;93(1):187–195.
- Damsky W, Singh K, Galan A, King B. Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid. JAAD Case Rep. 2020;6(2):133–135. doi:10.1016/j.jdcr.2019.11.016
- Basoulis D, Fragiadaki K, Tentolouris N, Sfikakis PP, Kokkinos A. Anti-TNFα treatment for recalcitrant ulcerative necrobiosis lipoidica diabeticorum: a case report and review of the literature. Metabolism. 2016;65(4):569–573. doi:10.1016/j.metabol.2015.12.014
- Janßen S, Jansen TM. Ulcerated necrobiosis lipoidica successfully treated with tofacitinib. Int J Dermatol. 2022;61(6):739–741. doi:10.1111/ijd.15960
- Lee JJ, English JC. Improvement in ulcerative necrobiosis lipoidica after Janus kinase–inhibitor therapy for polycythemia vera. JAMA Dermatol. 2018;154(6):733–734. doi:10.1001/jamadermatol.2018.0756
- Remicade (infliximab) [package insert]. Horsham, PA: Janssen Biotech, Inc; 2021.
- Xeljanz (tofacitinib) [package insert]. New York, NY: Pfizer Labs; 2022.
- Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84(4):1059–1067. doi:10.1016/j.jaad.2020.10.085
- Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20(21):5424. doi:10.3390/ijms20215424
- Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219–2229. doi:10.1056/NEJMoa2103629
- VTAMA (tapinarof) [package insert]. Long Beach, CA: Dermavant Sciences, Inc; 2022.